ATE428701T1 - Kristalline form von bisä(e)-7-ä4-(4-fluorphenyl)-6-isopropyl-2- - Google Patents

Kristalline form von bisä(e)-7-ä4-(4-fluorphenyl)-6-isopropyl-2-

Info

Publication number
ATE428701T1
ATE428701T1 AT04768376T AT04768376T ATE428701T1 AT E428701 T1 ATE428701 T1 AT E428701T1 AT 04768376 T AT04768376 T AT 04768376T AT 04768376 T AT04768376 T AT 04768376T AT E428701 T1 ATE428701 T1 AT E428701T1
Authority
AT
Austria
Prior art keywords
bisä
fluorophenyl
isopropyl
crystalline form
crystalline
Prior art date
Application number
AT04768376T
Other languages
English (en)
Inventor
Rebecca Booth
Peter Cittern
Jeffrey Crabb
John Horbury
David Jones
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34276833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE428701(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0321127A external-priority patent/GB0321127D0/en
Priority claimed from GB0404859A external-priority patent/GB0404859D0/en
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Application granted granted Critical
Publication of ATE428701T1 publication Critical patent/ATE428701T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
AT04768376T 2003-09-10 2004-09-08 Kristalline form von bisä(e)-7-ä4-(4-fluorphenyl)-6-isopropyl-2- ATE428701T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0321127A GB0321127D0 (en) 2003-09-10 2003-09-10 Chemical compounds
GB0404859A GB0404859D0 (en) 2004-03-04 2004-03-04 Chemical compound
PCT/GB2004/003829 WO2005023779A1 (en) 2003-09-10 2004-09-08 Crystalline form of bis [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6 -enoicacid] calcium salt

Publications (1)

Publication Number Publication Date
ATE428701T1 true ATE428701T1 (de) 2009-05-15

Family

ID=34276833

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04768376T ATE428701T1 (de) 2003-09-10 2004-09-08 Kristalline form von bisä(e)-7-ä4-(4-fluorphenyl)-6-isopropyl-2-

Country Status (31)

Country Link
US (4) US20060293355A1 (de)
EP (1) EP1663989B1 (de)
JP (1) JP2007505090A (de)
KR (1) KR20070019943A (de)
CN (1) CN1878760B (de)
AR (1) AR045628A1 (de)
AT (1) ATE428701T1 (de)
AU (1) AU2004270467B8 (de)
BR (1) BRPI0414236A (de)
CA (1) CA2537962C (de)
CO (1) CO5670355A2 (de)
CY (1) CY1109173T1 (de)
DE (1) DE602004020640D1 (de)
DK (1) DK1663989T3 (de)
ES (1) ES2324042T3 (de)
HR (1) HRP20090335T1 (de)
IL (1) IL174073A (de)
IS (1) IS2689B (de)
MX (1) MXPA06002761A (de)
MY (1) MY142615A (de)
NO (1) NO336358B1 (de)
NZ (1) NZ545785A (de)
PL (1) PL1663989T3 (de)
PT (1) PT1663989E (de)
RU (1) RU2363697C2 (de)
SA (1) SA04250297B1 (de)
SI (1) SI1663989T1 (de)
TW (1) TWI370817B (de)
UA (1) UA85062C2 (de)
UY (1) UY28501A1 (de)
WO (1) WO2005023779A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0011120D0 (en) * 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
AU2002318041B2 (en) 2001-07-13 2008-01-03 Astrazeneca Uk Limited Preparation of aminopyrimidine compounds
EP1323717A1 (de) 2001-12-27 2003-07-02 Dsm N.V. Prozess für die Herstellung von 2-(6-Substituierten-1,3-Dioxan-4-yl) Essigsäure Derivaten
EP1375493A1 (de) 2002-06-17 2004-01-02 Dsm N.V. Verfahren zur Herstellung von Dioxanessigsäureester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
KR101060215B1 (ko) 2002-12-16 2011-08-29 아스트라제네카 유케이 리미티드 피리미딘 화합물의 제조 방법
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
EP1948618A1 (de) * 2006-09-18 2008-07-30 Teva Pharmaceutical Industries Ltd. Kristallines rosuvastatin-kalzium
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
SI2752407T1 (sl) * 2009-01-14 2016-07-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalni kalcijev rosuvastatin trihidrat
EA021942B1 (ru) * 2009-01-15 2015-10-30 Эгиш Дьёдьсердьяр Зрт. Способ изготовления солей розувастатина
HUP0900285A2 (en) 2009-05-07 2011-01-28 Egis Gyogyszergyar Nyilvanosan Mukoedoe Reszvenytarsasag Rosuvastatin salts and preparation thereof
WO2011074016A1 (en) 2009-12-17 2011-06-23 Matrix Laboratories Ltd Novel polymorphic forms of rosuvastatin calcium and process for preparation of the same
HU230737B1 (hu) 2010-11-16 2018-01-29 EGIS Gyógyszergyár Nyrt Eljárás rosuvastatin só előállítására
CA2818007A1 (en) 2010-11-22 2012-05-31 Basf Se Multicomponent system of rosuvastatin calcium salt and sorbitol
WO2012143308A1 (en) 2011-04-18 2012-10-26 Basf Se Multicomponent crystalline system of rosuvastatin calcium salt and vanillin
WO2014050874A1 (ja) * 2012-09-27 2014-04-03 東和薬品株式会社 ロスバスタチンカルシウムの新規結晶形態およびその製造方法
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
JP6596339B2 (ja) 2014-02-06 2019-10-23 株式会社エーピーアイ コーポレーション ロスバスタチンカルシウム及びその中間体の製造方法
WO2017183040A1 (en) 2016-04-18 2017-10-26 Morepen Laboratories Limited New polymorphic form of crystalline rosuvastatin calcium & novel processes for crystalline as well as amorphous rosuvastatin calcium
CN105837516B (zh) * 2016-05-16 2018-07-10 山东新时代药业有限公司 一种瑞舒伐他汀钙晶型及其制备方法
EP3653329B1 (de) 2017-09-13 2023-10-11 JFE Steel Corporation Verfahren zum beidseitigen reibrührschweissen von metallplatten
WO2024157513A1 (ja) 2023-01-25 2024-08-02 Ｊｆｅスチール株式会社 テーラードブランク材、ならびに、テーラードブランク材の製造方法および製造設備

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645858A (en) * 1982-03-22 1987-02-24 G. D. Searle & Co. Pentanedioic acid derivatives
DE3741509A1 (de) * 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
AU3214689A (en) 1988-10-06 1990-05-01 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5026698A (en) * 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5278313A (en) * 1992-03-27 1994-01-11 E. R. Squibb & Sons, Inc. Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
DK0577040T3 (da) * 1992-07-02 1998-02-02 Hoechst Ag Fremgangsmåde til fremstilling af (3R,5S)6-hydroxy-3,,5-O-isopropyliden-3,5-dihydroxyhexansyre-tert.-butylester
SI1148049T1 (en) 1995-07-17 2005-02-28 Warner-Lambert Company Crystalline R-(R*,R*)$-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl -1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
US6278001B1 (en) * 1995-11-28 2001-08-21 L'oréal Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
PT907639E (pt) 1996-06-24 2003-06-30 Novartis Ag Compostos polimorficos
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
HUP0103021A3 (en) * 1998-12-10 2002-04-29 Kaneka Corp Process for producing simvastatin derivatives
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
WO2001022962A1 (en) 1999-09-30 2001-04-05 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
DE60018100T2 (de) 1999-11-17 2005-09-15 Teva Pharmaceutical Industries Ltd. Polymorphe form von atorvastatin-calcium
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
AU2000254249A1 (en) 2000-03-28 2001-10-08 Biocon India Limited Synthesis of (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-
GB0011120D0 (en) * 2000-05-09 2000-06-28 Avecia Ltd Process
GB0011163D0 (en) 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
IL155194A0 (en) 2000-10-05 2003-11-23 Biogal Pharmaceutical Co Ltd Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
IL155890A0 (en) 2000-11-16 2003-12-23 Teva Pharma HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
NL1017548C2 (nl) 2001-03-09 2002-09-10 Synthon Bv Een lactonisatie proces.
IN190564B (de) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
IL158525A0 (en) 2001-06-06 2004-05-12 Bristol Myers Squibb Co A process for preparing chiral diol sulfone derivatives
AU2002318041B2 (en) 2001-07-13 2008-01-03 Astrazeneca Uk Limited Preparation of aminopyrimidine compounds
AU2002324715B2 (en) 2001-08-16 2009-03-12 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
IL160043A0 (en) 2001-08-22 2004-06-20 Ciba Sc Holding Ag Process for the preparation of indole derivatives
WO2003026573A2 (en) 2001-09-24 2003-04-03 Merck & Co., Inc. Screening and selection methods for statin drug combinations
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
EP1323717A1 (de) 2001-12-27 2003-07-02 Dsm N.V. Prozess für die Herstellung von 2-(6-Substituierten-1,3-Dioxan-4-yl) Essigsäure Derivaten
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
EP1585736A2 (de) 2002-05-21 2005-10-19 Ranbaxy Laboratories, Ltd. Verfahren zur herstellung von rosuvastatin
EP1375493A1 (de) 2002-06-17 2004-01-02 Dsm N.V. Verfahren zur Herstellung von Dioxanessigsäureester
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
KR101060215B1 (ko) 2002-12-16 2011-08-29 아스트라제네카 유케이 리미티드 피리미딘 화합물의 제조 방법
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) * 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE10352659B4 (de) 2003-11-11 2007-09-13 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
WO2005054207A1 (en) * 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
US7241800B2 (en) * 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
US7161004B2 (en) * 2004-06-21 2007-01-09 Dr. Reddy's Laboratories Limited Processes to produce intermediates for rosuvastatin
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
KR101280096B1 (ko) 2005-06-29 2013-06-28 컴퓨메딕스 리미티드 전도성 브리지를 포함하는 센서 어셈블리
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process

Also Published As

Publication number Publication date
US20130225622A1 (en) 2013-08-29
CO5670355A2 (es) 2006-08-31
SI1663989T1 (sl) 2009-08-31
US20060293355A1 (en) 2006-12-28
IS8385A (is) 2006-03-30
IL174073A (en) 2014-03-31
AU2004270467B8 (en) 2008-09-18
JP2007505090A (ja) 2007-03-08
AR045628A1 (es) 2005-11-02
CA2537962C (en) 2012-10-23
PL1663989T3 (pl) 2009-08-31
KR20070019943A (ko) 2007-02-16
BRPI0414236A (pt) 2006-10-31
AU2004270467B2 (en) 2008-08-21
RU2363697C2 (ru) 2009-08-10
TW200526595A (en) 2005-08-16
IS2689B (is) 2010-10-15
UA85062C2 (uk) 2008-12-25
UY28501A1 (es) 2005-04-29
IL174073A0 (en) 2006-08-01
CN1878760B (zh) 2011-11-09
ES2324042T3 (es) 2009-07-29
PT1663989E (pt) 2009-06-09
AU2004270467A1 (en) 2005-03-17
WO2005023779A1 (en) 2005-03-17
CN1878760A (zh) 2006-12-13
CY1109173T1 (el) 2014-07-02
EP1663989B1 (de) 2009-04-15
SA04250297B1 (ar) 2008-11-18
US20100222373A1 (en) 2010-09-02
US20120059022A1 (en) 2012-03-08
US8436167B2 (en) 2013-05-07
HRP20090335T1 (hr) 2009-07-31
MXPA06002761A (es) 2006-12-14
EP1663989A1 (de) 2006-06-07
CA2537962A1 (en) 2005-03-17
MY142615A (en) 2010-12-15
DK1663989T3 (da) 2009-07-06
TWI370817B (en) 2012-08-21
RU2006111354A (ru) 2007-10-27
NZ545785A (en) 2010-03-26
HK1090361A1 (en) 2006-12-22
DE602004020640D1 (de) 2009-05-28
NO20061181L (no) 2006-03-29
NO336358B1 (no) 2015-08-03

Similar Documents

Publication Publication Date Title
ATE428701T1 (de) Kristalline form von bisä(e)-7-ä4-(4-fluorphenyl)-6-isopropyl-2-
DE602004020156D1 (de) Verwaltung von Rahmenbursts
IS8348A (is) Samrunnin heteróhringasambönd
ATE404537T1 (de) Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung
SE0301569D0 (sv) Novel compounds
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
EP1660436A4 (de) Cathepsininhibitoren
DE602004019555D1 (de) Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone
ATE364610T1 (de) Kristalline polymorphe form von irinotecan- hyrochlorid
DE502004011575D1 (de) Verwendung von Dioldimerfettsäureestern
DE602004012925D1 (de) Protokoll zur Erbringung von Diensten
DE602004022935D1 (de) Verbesserungen des stimulationserfolgs-managements
IS8399A (is) Form fjölgervings 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólíns
IS7833A (is) Efnasambönd með sameinaða heteróhringi
ITPS20030026A1 (it) Struttura di osteotomo.
DK1633719T3 (da) Substituerede spirobenzazepiner
NO20040868L (no) Ruting av meldinger
ATE499348T1 (de) Stabiler polymorph von bifeprunoxmesilat
DE602004024640D1 (de) Reinigung von titantetrachlorid
NO20055097D0 (no) Krystallinske N-formyl-hydroksylaminforbindelser
DK1472412T3 (da) Byggesæt af brosten
FR2864109B1 (fr) Croissance organisee de nano-structures
ATE410417T1 (de) Kristallmodifikationen von triazinylaminostilbenen
ATE360010T1 (de) Heterocyclische retioidverbindungen
ATE556047T1 (de) Kristalline feste form der (2s-5z)-2-amino-7-

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1663989

Country of ref document: EP